Altamira Therapeutics (CYTO) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free CYTO Stock Alerts $1.56 +0.12 (+8.33%) (As of 03:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 4:48 AM | americanbankingnews.comShort Interest in Altamira Therapeutics Ltd. (NASDAQ:CYTO) Expands By 67.5%May 1, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationApril 24, 2024 | msn.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 15, 2024 | finance.yahoo.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptApril 10, 2024 | finance.yahoo.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 4, 2024 | globenewswire.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024March 26, 2024 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 26, 2024 | markets.businessinsider.comCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 25, 2024 | msn.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | globenewswire.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalJanuary 24, 2024 | marketwatch.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | msn.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | finance.yahoo.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 8, 2024 | finance.yahoo.comAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitDecember 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 13, 2023 | marketbeat.comTrading was temporarily halted for "CYTO" at 09:12 AM with a stated reason of "LULD pause."December 13, 2023 | marketbeat.comTrading was temporarily halted for "CYTO" at 07:12 PM with a stated reason of "News pending."December 11, 2023 | msn.comAltamira shares sink over 40% on corporate, stock split updatesDecember 11, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Down 50% TodayDecember 11, 2023 | finance.yahoo.comAltamira Therapeutics Provides Investor and Business UpdateDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | benzinga.comThinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?November 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNovember 20, 2023 | uk.finance.yahoo.comTrending tickers: Microsoft | Bitcoin | Altamira | AshteadNovember 17, 2023 | msn.comAltamira stock surges after deal to sell 51% stake in MedicaNovember 17, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 160% Today?November 17, 2023 | marketwatch.comAltamira Therapeutics Shares Surge on Sale of Bentrio UnitNovember 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNovember 10, 2023 | finance.yahoo.comAltamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNovember 3, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 28% Today?September 14, 2023 | marketwatch.comAltamira Therapeutics Shares Rise on Positive Bentrio Trial ResultsSeptember 14, 2023 | finance.yahoo.comAltamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisSeptember 13, 2023 | insidermonkey.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call TranscriptSeptember 12, 2023 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 12, 2023 | finance.yahoo.comAltamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 8, 2023 | markets.businessinsider.comAltamira Therapeutics Ltd Registered Shs hosts conference call for investorsSeptember 6, 2023 | finance.yahoo.comAltamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thAugust 23, 2023 | uk.finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 23, 2023 | finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13July 20, 2023 | finance.yahoo.comAltamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaJuly 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalJuly 6, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Getting HammeredJuly 6, 2023 | finance.yahoo.comAltamira Therapeutics Announces Pricing of $5.0 Million Public OfferingJuly 5, 2023 | finance.yahoo.comAltamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. CYTO Media Mentions By Week CYTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTO News Sentiment▼0.970.55▲Average Medical News Sentiment CYTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTO Articles This Week▼41▲CYTO Articles Average Week Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATXI News VRPX News ONCO News NTBL News SNOA News SXTP News CWBR News CNSP News SLRX News CYCC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTO) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
